Clinical trials: Viruses
Hepatitis C, Viruses
TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.
The purpose of this study is to determine whether TMC435 influences the activity of certain drug-degrading proteins in the human body.
- Trial name
- NCT00866853
- Testing
- TMC435
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Human Immunodeficiency Viruses, Kidney Failure
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients
Tenofovir (TDF)-containing regimens may be associated with decreasing renal function in HIV-infected patients concurrently treated with boosted PI's and/or have co-morbid conditions including diabetes mellitus, hypertension…
- Conditions
- Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
- Trial name
- NCT00551655
- Where
- United States
- Volunteers
- 684 people
- Sponsor
- AIDS Arms Inc.